Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck KGaA Turns To Outsider Oschmann To Head Pharma Unit

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck & Co.'s emerging markets head Stefan Oschmann will succeed Merck KGaA's Elmar Schnee as head of pharmaceuticals effective Jan. 1.

You may also be interested in...



Merck Serono/Dr. Reddy's Biosimilars Deal Includes Co-Commercialization In U.S.

In most of the world, Germany's Merck Serono will have exclusive rights and India’s Dr. Reddy's will receive royalties on the oncology biosimilars which will be developed as part of the collaboration; but in the U.S. and select emerging markets, the Indian company retains co-commercialization rights.

Merck Serono/Dr. Reddy's Biosimilars Deal Includes Co-Commercialization In U.S.

In most of the world, Germany's Merck Serono will have exclusive rights and India’s Dr. Reddy's will receive royalties on the oncology biosimilars which will be developed as part of the collaboration; but in the U.S. and select emerging markets, the Indian company retains co-commercialization rights.

Merck KGaA 2010 Results Marred By Cladribine And Poor OTC Growth

Millipore acquisition boosts 2010 results for Germany's Merck, but pharma strategy remains unclear.

Related Content

Topics

UsernamePublicRestriction

Register

PS071601

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel